Leerink Swann Starts Raptor Pharmaceuticals (RPTP) at Outperform; Taking Flight in Cystinosis and Beyond
Tweet
Share
E-mailGet Alerts RPTP Hot Sheet
Price: $9.00 --0%
Rating Summary:
6 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann initiates coverage on Raptor Pharmaceuticals (NASDAQ: RPTP) with a Outperform. PT $9.00.
Leerink analyst says, "RPTP is a late-stage biopharmaceutical company focused on developing RP-103 (delayed-release DR Cysteamine), which we believe may become the new standard of care and warrant premium pricing for the ultra-orphan indication of nephropathic cystinosis (NC). RPTP also has plans to study RP-104 (DR Cysteamine) in NASH, which could offer upside longer term."
For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $6.26 yesterday.
Leerink analyst says, "RPTP is a late-stage biopharmaceutical company focused on developing RP-103 (delayed-release DR Cysteamine), which we believe may become the new standard of care and warrant premium pricing for the ultra-orphan indication of nephropathic cystinosis (NC). RPTP also has plans to study RP-104 (DR Cysteamine) in NASH, which could offer upside longer term."
For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $6.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- UBS Starts Schrodinger (SDGR) at Neutral
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
